Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

New FFR Measuring Device to Guide Coronary Revascularization with Our Preferred Wire

Measuring fractional flow reserve (FFR) with a 0.014 pressure wire is the standard to assess the functional significance of epicardial coronary artery stenosis. The use of FFR in the clinical practice lags despite strong supporting evidence. Some of the reasons behind this are technical aspects, like pressure wire handling limitations when assessing certain lesions, or how frustrating it can be to lose position and to have to recalibrate pressures when there is too much drift and we are no longer sure the value we have obtained is the real one.

Nuevo dispositivo para medición del FFR permite cruzar la lesión con nuestra guía preferida

An optical pressure monitoring microcatheter has recently been developed, which can be advanced over a traditional 0.014 guidewire (the one we prefer, the one we use in most cases) and allows us to pull back without losing lesion position. The potential disadvantage of this system might be that it has a higher profile than the pressure wire alone, and this might exaggerate stenosis values, overestimating FFR measurement.


Read also: What Is the Long-Term Outcome of Lesions Deferred Using FFR/iFR?”


 

Primary end point was the difference between both measurements, assuming as gold standard the pressure wire value.

 

The mean difference between the microcatheter and the pressure wire measurements was 0.022 (CI 95%, −0.029 to −0.015). On multivariable analyzis, reference vessel diameter (p=0.027) and lesion length (p=0.044) were independent predictors of bias between the 2 measurements.


Read also: Physiologically Assessing Intermediate Stenosis: Could FFR Be Replaced?”


 

Conclusion

 

FFR measurement with Navvus microcatheter, especially designed to this end, tends to render lower values than pressure wire derived FFR, but the diagnostic and therapeutic impact of this difference seems minimal in most cases.  

 

Editorial Comment

From the physiological point of view, adding a microcatheter will most likely have a higher impact in lesion flow than pressure wire alone, leading to a higher gradient and, ultimately, a lower FFR, especially in longer lesions and thinner vessels.

 

The more severe the measurement, the bigger the difference observed vs. the pressure wire, though in most cases, both values resulted functionally significant, so the clinical impact that could change diagnosis and therapy was not modified.

 

A second generation of microcatheters with a much lower profile is already available, though it has not been tested in this study. On the other hand, FFR guidewires have also evolved, with better torque and handling. At some point, one of these wires will cross the finish line and, most likely, it will be the easiest to handle.

 

Original title: ACIST-FFR Study (Assessment of Catheter-Based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement).

Reference: William F. Fearon et al. Circ Cardiovasc Interv. 2017 Dec;10 (12).


Suscríbase a nuestro newsletter semanal

Reciba resúmenes con los últimos artículos científicos

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...